Modified FXN Gene Therapy for Friedreich Ataxia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Friedreich ataxia lack effectiveness in addressing the underlying cause of frataxin deficiency, leading to progressive neurodegeneration and cardiomyopathy, with no existing therapy capable of stopping or slowing the disease's negative effects.
Innovation Solution
Modified nucleic acids encoding frataxin (FXN) genes are introduced using vectors such as recombinant adeno-associated virus (rAAV) to increase expression levels of wild-type mitochondrial frataxin protein, specifically altering GC nucleotide content and reducing CpG dinucleotides to suppress gene silencing, thereby targeting cardiac and neuronal tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the wild-type FXN gene is used for gene therapy, then the gene can be delivered to target cells, but the gene expression is silenced due to CpG dinucleotide methylation
Solution Approach 1:
The patent extracts and removes the harmful CpG dinucleotides from the FXN gene sequence. Specifically, the wild-type FXN gene containing CpG dinucleotides is modified to create a variant with reduced or eliminated CpG sites, thereby removing the cause of methylation-based gene silencing while preserving the therapeutic function of the gene.
Solution Approach 2:
The patent changes the nucleotide sequence parameters of the FXN gene by altering the GC content and specifically reducing CpG dinucleotide frequency. This parameter modification transforms the gene from a silencing-prone sequence to one that resists methylation-based repression, ensuring reliable expression in target cells.
2Productivity
If standard FXN gene therapy approaches are used, then treatment can be administered, but the underlying frataxin deficiency is not effectively addressed
Solution Approach 1:
The patent optimizes the FXN gene sequence parameters including GC content (increased to 60-80%) and codon usage to maximize frataxin protein expression. These parameter changes enhance the productivity of the therapeutic protein while ensuring reliable and sustained expression levels that effectively address the underlying deficiency.
Solution Approach 2:
The patent performs preliminary optimization of the FXN gene sequence before delivery to target cells. By pre-modifying the gene to have enhanced GC content and optimized codons, the system ensures that upon expression, the frataxin protein is produced at high levels, effectively addressing the deficiency from the outset.
3Reliability
If the FXN gene is modified to increase GC content, then gene expression is enhanced, but the gene becomes more susceptible to mutational changes
Solution Approach 1:
The patent carefully controls the GC content parameter within an optimal range (60-80%) rather than maximizing it indefinitely. This balanced parameter change achieves enhanced expression while maintaining sequence stability, as excessive GC content could lead to unwanted mutational patterns.
Solution Approach 2:
The patent applies local quality modifications by selectively optimizing specific regions of the FXN gene. Rather than uniformly increasing GC content throughout the entire gene, the modification is applied strategically to specific codon positions and regulatory elements, achieving expression enhancement while preserving overall sequence stability.
Data Source
AI summary
The present invention relates to a modified FXN gene providing for increased expression of the encoded protein frataxin that can be used for treatment of Friedreich ataxia.